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angiographically. Statistical analysis was performed using SPSS for Windows
(version 13.0) and the cutoff was optimized by ROC curves. 
Results: For 9 months, troponin Ic assays were performed using 1671 samples
from patients admitted to the emergency department. Only 378 had troponin I
levels of more than 0.01 μg / l (the 99th percentile value for VIDAS troponin). 
Out of the 378 patients concerned, 53 were hospitalized in the cardiology
department and 25 were diagnosed as having an acute coronary syndrome.
The clinical sensitivity for Troponin Ic assay was 72% and specificity was
50% with cutoff equal to 0.18 μg. Area under the receiver-operating-charac-
teristic curve was 0.6 
Conclusion: The troponin assay is often used in emergency departments
during the initial assessment of chest pain. Knowing troponin’s cutoff in our pop-
ulation allows us to have a better management. In the near future, the use of a sen-
sitive assay for troponin I would improve early diagnosis of acute myocardial
infarction and risk stratification, regardless of the time of chest-pain onset.
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Introduction: The pathogenetic mechanism of premature myocardial infarc-
tion (MI) remains unknown. A Common mutation C677T in methylenetetrahydro-
folate (MTHFR) gene, involved in the metabolism of homocysteine, has been
suggested to play a role in increasing cardiovascular disease risk. The aim of the
present study was to investigate the association between the C677Tpolymorphism
of the MTHFR gene and MI in the Tunisian male population.
Methods: A total of 316 unrelated patients with MI and 348 controls were
included in this study. DNA was extracted from the blood and genotypes were
determined by polymerase chain reaction, restriction mapping with HinfI and
gel electrophoresis. 
Results: The distribution of MTHFR C677T genotypes followed the Hardy-
Weinberg equilibrium. The distribution of MTHFR genotypes and the frequency
of alleles were similar in MI patients and controls. The TT genotype was present
in 8.7% of controls as compared to 10.8% of MI patients (p=0.41, OR=1.06; 95%
CI: 0.53-2.12). The frequency of T allele was also similar in patients with MI
compared with controls (0.30 vs. 0.28; p=0.172). There was also no significant
association between C677T genotypes and the risk of MI. 
Conclusion: These finding suggest that the C677T polymorphism of the
MTHFR gene was not associated with MI in the Tunisian male population. 
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Objectives: To evaluate the biological response and clinical outcome at
30 days after discharge of acute coronary syndrome (ACS) patients treated
with prasugrel 10mg in real life
Methods: Three hundred eighteen consecutive ACS patients undergoing
PCI and treated with a daily dose of prasugrel 10 mg were included in this
prospective bicentric observational, study. On-treatment platelet reactivity was
measured 30 days after discharge with the VASP index, VerifyNow and Light
Transmission Aggregometry. Ischemic events (cardiovascular death, myocar-
dial infarction, and stent thrombosis) and bleeding (Bleeding Academic
Research Consortium (BARC) definition) were systematically recorded at a
specific consultation one month after discharge.
Results: Two thirds of the patients presented with a ST-Elevation Myocar-
dial Infarction, they were 59.4 ±13 year old with 12.6% of elderly (>75 y/o)
and 25% of diabetics. High on treatment platelet reactivity (HPR) according
to each specific definition (VASP>50%, PRU> 235, RPA >46.2%) was
observed in 6%, 4% and 4.9 % respectively. Correlations between the various
platelet function tests were: RPA and PRU (r=0.8; p<0.01), PRU and VASP
(r=0.63; p<0.01) and VASP and RPA (r= 0.56; p<0.01). At 30 days of follow-
up the rate of ischemic events was 1.6% (one cardiovascular death, one ACS
and 3 stent thrombosis) with no major bleeding complication (BARC 3). How-
ever, the rate of nuisance bleeding (BARC 1) and minor bleeding (BARC 2)
were 12.9% and 2.8 % respectively. 
Conclusions: In real life, only few ACS patients treated with prasugrel 10 mg
has HPR and the drug seems to have an acceptable safety profile at one month. 
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Drug-eluting stent (DES) implantation is a routine in our daily clinical
practice since many years, but its long-term clinical and angiographic outcome
is not clear especially in off-label indications. Determine demographic, angio-
graphic and procedural characteristics of these patients and the long term out-
come and independent predictors of restenosis is the goal of our study.
Methods and results: We analyzed 1053 consecutive patients (mean age
60.2±10.8 y, 76.7% men, 57.2% diabetic) who had undergone percutaneous coro-
nary intervention between june 2002 and June 2009, at a median follow-up of
43±20 months available in 94.9% patients. We treated 131 bifurcated lesions, 108
coronary total occlusion, 521 lesions >18 mm long, 318 vessel diameter <2.5 mm
and 480 multi-vessels disease patients. We implanted 1.5 ±0.5stents per patient
and angiographic control was performed in 19.2% cases. Rates of acute and late
stent thrombosis were 0.75% and 0.47% respectively. 22 patients died from car-
diac causes, 45 had acute myocardial infarction, and 24 had recurrent angina. 47
patients (4.5%) had target lesion revascularization and 87 (8.26%) target vessel
failure. The restenosis rate was 4.9% (52). Multivariate analysis identified as inde-
pendent predictors of restenosis: pre balloon dilatation (odd ratio [OR]: 13, 95%
confidence interval [CI]: 1.1-22.5, P=0.03) and coronary total occlusion lesion,
(OR: 2.3, 95% CI: 1.3-12.4, P<0.01). Diabetes mellitus and multi-vessel lesion
were not associated with higher risk of restenosis (mean freedom survival was
respectively 92 months vs. 102, p=0.4 and 110 months vs. 91, p=0.3). More, in
our experience we observed a dramatically decrease of restenosis rate inside tow
critical periods: 2004-2005 and 2007-2008: in relation with dapt regimen, new
generation of DES , balloon post-dilatation and the learning curve.
Conclusions: In our experience, we report a reasonable long-term prog-
nosis even in high-risk patients.Total coronary occlusion and balloon pre-dil-
atation are independent factors of restenosis 
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Background. Transport of patients with ST elevation myocardial infarc-
tion (STEMI) is an essential step for the management and outcome of these
